Evidence map›Paper›PMID 25310302›Full record

ArticleBone marrow transplantation2015

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy.

C Girmenia, G M Rossolini, A Piciocchi, A Bertaina, G Pisapia, D Pastore, S Sica, A Severino, L Cudillo, F Ciceri and 6 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 87 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04431934 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Open-label, Randomized Study to Assess the Efficacy of a Probiotic or Fecal Microbiota Transplantation (FMT) on the Eradication of Rectal Multidrug-resistant Gram-negative Bacilli (MDR-GNB) Carriage (PROFTMDECOL)

TypeinterventionalSponsorHospital Clinic of BarcelonaRan2020 to 2023Enrolled437ConditionsCARRIER STATEArmsPROBIOTIC, FMT REGIMEN
NCT06342115 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.

TypeinterventionalSponsorBeneficência Portuguesa de São PauloRan2025 to 2026Enrolled176ConditionsFebrile NeutropeniaArmsCeftolozane-Tazobactam, Meropenem
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Central nervous system infections caused by carbapenem-resistant klebsiella pneumoniae after CAR T-cell therapy in a patient with preexisting colonization: a case report and literature review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Effectiveness of Bath Wipes After Hematopoietic Cell Transplantation: A Randomized Trial.Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
    Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Carbapenemase-ProducingOpen forum infectious diseases · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. The Characterisation of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024
    Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 2 countries.

C GirmeniaDipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
G M Rossolini1] Dipartimento di Biotecnologie Mediche, University of Siena, Siena, Italy [2] Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy [3] SOD Microbiologia e Virologia, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
A PiciocchiFondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Data Center, Rome, Italy.
A BertainaUnità Operativa di Oncoematologia, Ospedale pediatrico Bambino Gesù, Rome, Italy.
G PisapiaDivisione di Ematologia con Unità di Trapianto di Midollo- Ospedale S.G. Moscati, Taranto, Italy.
D PastoreUO di Ematologia con Trapianto, Dipartimento di Emergenza e Trapianto d'Organo, University of Bari, Bari, Italy.
S SicaDivisione di Ematologia-Istituto di Ematologia, Policlinico A. Gemelli, Università Cattolica S. Cuore, Rome, Italy.
A SeverinoUOC di Ematologia e Trapianti di Cellule Staminali, Az. Osp. S.Camillo-Forlanini, Rome, Italy.
L CudilloFondazione Policlinico Tor Vergata, Unità di Trapianto Cellule Staminali, University Tor Vergata, Rome, Italy.
F CiceriUnità operative di Ematologia e trapianto Midollo Osseo, Ospedale San Raffaele, Milan, Italy.
R ScimèUOC di Ematologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
L LombardiniCentro Nazionale Trapianti, Istituto Superiore di Sanità, Rome, Italy.
C ViscoliDipartimento di Malattie Infettive, IRCCS S. Martino University Hospital-IST, Genoa, Italy.
A RambaldiDivisione di Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Gruppo Italiano Trapianto Midollo Osseo GITMO
Policlinico Umberto I · ITAzienda Ospedaliera San Camillo-Forlanini · ITAzienda Ospedaliera S.Giuseppe Moscati · ITBambino Gesù Children's Hospital · ITIRCCS Ospedale San Raffaele · ITOspedale Papa Giovanni XXIII · ITOspedale Vincenzo Cervello · ITPoliclinico Tor Vergata · ITFondazione Gimema Onlus · ITIstituto Superiore di Sanità · ITMartin University · USOspedale Policlinico San Martino · ITUniversity of Bari Aldo Moro · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections by carbapenem-resistant Klebsiella pneumoniae (CRKp) represent a challenging problem after SCT. A retrospective survey (January 2010 to July 2013) involving 52 Italian centers was performed to assess the epidemiology and the prognostic factors of CRKp infections in auto- and allo-SCT. Cases of CRKp infection were reported in 53.4% of centers. CRKp infections were documented in 25 auto-SCTs and 87 allo-SCTs, with an incidence of 0.4% (from 0.1% in 2010 to 0.7% in 2013) and 2% (from 0.4% in 2010 to 2.9% in 2013), respectively. A CRKp colonization documented before or after transplant was followed by an infection in 25.8% of auto-SCT and 39.2% of allo-SCT patients. The infection-related mortality rates were 16% and 64.4%, respectively. A pre-transplant CRKp infection (hazard ratio (HR) 0.33, 95% confidence intervals (CIs) 0.15-0.74; P=0.007) and a not CRKp-targeted first-line treatment (HR 2.67, 95% CI 1.43-4.99; P=0.002) were independent factors associated with an increased mortality in allo-SCT patients who developed a CRKp infection. Our study shows challenging findings of CRKp infections in SCT patients in Italy particularly after allo-SCT. The detection of carriers and the definition of early therapeutic strategies represent critical aspects of the management of CRKp infections after SCT.

Indexed as

CarbapenemsDrug Resistance, BacterialKlebsiella pneumoniaeStem Cell TransplantationAdolescentAdultAgedAllograftsAutograftsFemaleHematologic DiseasesHumansItalyKlebsiella InfectionsMaleMiddle AgedCarbapenems

Identifiers

PMID25310302
OpenAlexW2011086964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.